- Revance Announces China Market License Agreement with Fosun Pharma for RT002
- Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
- Revance to Participate in Upcoming Investor Conferences
- Revance to Participate in the Credit Suisse Healthcare Conference
- Revance Releases Third Quarter 2018 Results
- Revance Therapeutics to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018
- Revance Therapeutics Appoints Tobin C. Schilke as Chief Financial Officer
- Revance to Participate in the Cantor Fitzgerald 2018 Global Healthcare Conference
- Revance Receives Great Place to Work Certification
As of last trade,
Revance Therapeutics Inc (RVNC:NMQ) traded at 22.06, 12.43% above the 52 week low of 19.62 set on Nov 27, 2018.
19.62Nov 27 201837.45Jan 03 2018
Markit short selling activity
|Market cap||803.74m USD|
|EPS (TTM)||-3.96 |
Data delayed at least 15 minutes, as of Dec 12 2018 20:22 GMT.